Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
2101-2120 of 2,120 trials

Cerebrolysin for Recovery After Ischemic Stroke

We are studying whether Cerebrolysin can improve upper limb function and overall recovery in patients after an ischemic stroke. Participants will be compared to those receiving a placebo to assess various health outcomes.

Ischaemic Stroke3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesNeurology

Gastric Cancer: Intraperitoneal Irinotecan Study

We are exploring a new treatment combining intraperitoneal irinotecan with standard therapy for patients with gastric cancer that has spread to the abdomen. This study aims to evaluate its safety, effectiveness, and impact on quality of life.

Gastric Peritoneal Metastases>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementOncology

Immunotherapy for High-Risk Oral Disorders: APHRODITE Trial

We are testing a new immunotherapy to see if it can prevent high-risk oral disorders from turning into cancer. The study will also look at the treatment's safety and its effects on patients' quality of life.

Oral Disorders>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncologyOtolaryngology

Metastatic Non-Small Cell Lung Cancer: BMS-986504 Treatment Study

We are studying a new drug, BMS-986504, combined with pembrolizumab and chemotherapy for patients with metastatic non-small cell lung cancer and a specific genetic deletion. The goal is to see if this combination improves survival compared to a placebo treatment.

Metastatic Non-Small Cell Lung CancerEfficacy phase (II)Confirmation phase (III)Investigational MedicinesCost ReimbursementOncology

IgA Nephropathy: Atacicept Treatment Study

We are testing a new medication, atacicept, to see if it helps patients with IgA nephropathy by reducing a specific protein in the blood. We will also monitor its safety and how it affects other immune factors.

IgA Nephropathy (Berger's Disease)1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesNephrology

Cangrelor for Acute Ischemic Stroke Treatment

We are studying the safety and effectiveness of an intravenous medication called Cangrelor for patients with acute ischemic stroke and significant carotid artery blockage. This trial aims to see if it helps improve blood flow during emergency stenting procedures.

Ischemic Stroke with Large Artery Occlusion>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyNeurology

Hereditary Angioedema: Navenibart Treatment Study

We are studying whether navenibart can help prevent attacks in adults and adolescents with hereditary angioedema. The trial will also look at its safety and how it affects quality of life.

Hereditary Angioedema1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyInternal Medicine

Advanced Solid Tumors: MK-1084 Treatment Study

We are studying the effects of MK-1084, both alone and with cetuximab, in patients with advanced solid tumors that have a KRAS G12C mutation. The goal is to see how well these treatments work and how safe they are.

Malignant Neoplasm with KRAS G12C Mutation>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Rheumatoid Arthritis: Tulisokibart Study

We are testing a new medication called tulisokibart for people with rheumatoid arthritis to see if it helps reduce symptoms better than a placebo. The study will also assess the safety and tolerability of this treatment.

Rheumatoid Arthritis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesRheumatology

Type 2 Diabetes: SGLT-2 Inhibitors and Heart Health

We are studying how SGLT-2 inhibitors may improve heart function and nerve health in people with type 2 diabetes. This research aims to understand the connection between these medications and heart regulation.

Type 2 DiabetesMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCardiologyEndocrinologyNeurology

Lung Cancer: Zipalertinib with Chemotherapy

We are studying whether adding zipalertinib to chemotherapy helps lung cancer patients with uncommon EGFR mutations after surgery. This trial compares the new treatment to a placebo combined with standard chemotherapy.

Non-small Cell Lung Cancer (NSCLC)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementOncology

RSV Immunization Study: Nirsevimab for Infants

We are studying how the nirsevimab immunization affects infants' immune responses to RSV infections. This research aims to understand the role of age, weight, and maternal antibodies in developing immunity.

Healthy Infants1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

Blood Cancer Treatment: Ciltacabtagene Autoleucel

We are studying the effects of a new infusion treatment for patients with blood cancers. The trial compares different ways of administering the treatment to see which is more effective and safe.

Newly Diagnosed Multiple MyelomaEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Open-Heart Surgery: Parasternal Block for Pain Relief

We are studying whether a special nerve block helps reduce pain and opioid use in patients recovering from open-heart surgery. This trial aims to improve recovery experiences for these patients.

Postoperative Pain Management>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal MedicineOtolaryngology

CIT-013 for Inflammatory Mediated Immune Diseases

We are studying how a new treatment, CIT-013, spreads in the body of patients with inflammatory mediated immune diseases. We also want to learn about its safety and how the body handles it.

Inflammatory Mediated Immune Diseases≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesRheumatology

Kidney Protection: Semaglutide and Finerenone in CKD

We are studying how semaglutide and finerenone may help protect the kidneys in people with chronic kidney disease. This includes patients with and without diabetes to explore their effects and mechanisms.

Chronic Kidney Disease6-12 monthsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyNephrology

Influenza Vaccine Study: Seqirus H5N8

We are investigating how well the Seqirus H5N8 influenza vaccine works in adults who have been previously vaccinated and those who have never received an H5 vaccine. The study aims to assess immune responses and safety in both groups.

H5N1 Influenza Immunization≤3 monthsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesInfectious Diseases

Influenza Vaccine Study for Adults

We are assessing a new mRNA-based vaccine to see how well it boosts the immune response and its safety in adults aged 18 and older. This study aims to improve protection against seasonal influenza.

Human Influenza6-12 monthsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInfectious Diseases

Metastatic Breast Cancer: Trastuzumab-Deruxtecan Study

We are studying how body weight influences the effects and side effects of trastuzumab-deruxtecan in patients with metastatic breast cancer. This research may help improve treatment strategies for different body types.

Metastatic Breast Cancer>2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineOncology

COVID-19 Vaccine Study: BIMERVAX® LP.8.1

We are evaluating the safety and immune response of the BIMERVAX® LP.8.1 vaccine against COVID-19 variants. This study aims to understand how well it works in generating antibodies to fight the virus.

COVID-19≤3 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesInfectious Diseases